Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Classifica tra le azioni #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Prezzo delle azioni
$28.53
Capitalizzazione di mercato
$1.96B
Variazione (1 giorno)
-1.65%
Variazione (1 anno)
109.32%
Paese
IE
Scambia GH Research PLC (GHRS)

Categoria

Storico del rendimento da dividendi per GH Research PLC (GHRS)
Il rendimento da dividendi (TTM) di GH Research PLC (simbolo azionario: GHRS) al 2026 è: 0
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per GH Research PLC (GHRS) da 2026 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
Non abbastanza dati per le date fornite.
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH